Navigation Links
Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics' Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
Date:1/31/2011

DURHAM, N.C., Jan. 31, 2011 /PRNewswire/ -- Argos Therapeutics announced today that interleukin (IL)-12 secretion can predict the potency of the company's Arcelis™ dendritic cell (DC) immunotherapy and can be used as a potency marker in a Phase 3 clinical trial testing the company's lead product, AGS-003, in metastatic renal cell carcinoma (mRCC). In vitro results published in the Journal of Immunotherapy demonstrate that the potency of mature CD40L RNA electroporated DCs correlates with IL-12 secretion by tracking the multifunctional CD8(+)/CD28(+) memory T-cell responses.

"The dependence of AGS-003-induced memory cytotoxic T lymphocytes on IL-12 secretion from DCs makes it an attractive marker for DC potency," said Charles Nicolette, Ph.D., chief scientific officer and vice president of research and development of Argos. "Using IL-12 secretion as a potency marker is highly relevant to AGS-003 since it is directly linked to the mechanism of action and it is equally relevant to other Arcelis products such as AGS-004 for HIV."

Jeff Abbey, president and chief executive officer of Argos, added, "Identifying an effective potency marker for our upcoming Phase 3 clinical trial in mRCC is a significant step in the advancement of our pipeline. We are in the process of securing funding to begin the trial by mid-2011. Our Arcelis HIV program is currently being tested in a Phase 2b study co-funded by the NIH."

Electroporation of mature DCs with RNA-encoding CD40L greatly enhances the production of IL-12, a proinflammatory cytokine necessary for the induction of T-cell immunity. In vitro results presented in the Journal of Immunotherapy reveal a correlation between the priming of CD28(+) antigen-reactive effector memory CTL displaying three or four simultaneous effector functions and the quantity of IL-12 produced by post-maturation RNA electroporated DC. By using multiparameter flow cytometry, the quantities of IL-12 needed to prime naive antigen-reactive T cells to simultaneously produce interferon-gamma and tumor necrosis factor-alpha in the presence or absence of IL-2 secretion in conjunction with lytic activity defined by CD107a expression can be used to determine the overall potency of a DC product. In the presence of IL-12, CTL differentiation toward lytic function is not accompanied by a reduction in the secretion of interferon-gamma and tumor necrosis factor-alpha. Therefore, by measuring the availability of IL-12 one can predict the potency of a DC immunotherapeutic in relation to its ability to drive distinct effector memory CTL subsets with multifunctional activities.

Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.

About Argos Therapeutics, Inc.Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www.argostherapeutics.comContacts:David Schull or Andreas MarathovouniotisRusso Partners LLC(212) 845-4271 or (212) 845-4235david.schull@russopartnersllc.com or andreas.marathis@russopartnersllc.comJeff AbbeyArgos Therapeutics(919) 287-6308jabbey@argostherapeutics.com
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Interleukin Genetics Reports Third Quarter 2010 Financial Results
2. Interleukin Genetics Moves Trading of Stock to OTCQB Marketplace
3. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2010 Results
4. Interleukin Genetics, Inc. Announces Conference Call to Discuss First Quarter 2010 Results
5. NYSE Amex Provides Interleukin Genetics, Inc. Extension To Meet Continued Listing Standards
6. Interleukin Genetics to Raise $5.3 Million in Registered Direct Offering
7. Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis
8. Interleukin Genetics, Inc. Announces Positive Results from Clinical Study Evaluating Genetic Tests Impact on Weight Loss
9. Interleukin Genetics Presents Research Linking Vertebral Fractures to Gene Variations in Asian Women With Osteoporosis
10. Interleukin Genetics and Geisinger to Collaborate on Genetic Tests to Predict Weight Loss Success
11. Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... 2016 , ... Research has shown that building shame resilience ... and level of relapse. , At the 2016 iaedp Symposium, the ... the critical tasks of the recovery phase and beyond including relapse prevention and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
Breaking Medicine News(10 mins):